BENIGN RENAL ANGIOMYOLIPOMA WITH REGIONAL LYMPH NODE INVOLVEMENT: Report of a Case Showing Enlargement Five Years After Nephrectomy

2008 ◽  
Vol 37 (11) ◽  
pp. 1853-1858
Author(s):  
Toshiaki Manabe ◽  
Takuya Moriya ◽  
Masatoshi Kimoto
1984 ◽  
Vol 34 (4) ◽  
pp. 889-893
Author(s):  
Toshiaki Manabe ◽  
Yoshikazu Tasaka ◽  
Masamichi Amano ◽  
Takeshi Okunobo

Cancer ◽  
2003 ◽  
Vol 97 (10) ◽  
pp. 2425-2431 ◽  
Author(s):  
Igor Frank ◽  
John C. Cheville ◽  
Michael L. Blute ◽  
Christine M. Lohse ◽  
Ajay Nehra ◽  
...  

2018 ◽  
Vol 2 (1) ◽  
Author(s):  
Jack Cuzick

Abstract There is a somewhat confused belief that a biomarker must show an interaction effect with a treatment before it can be used to determine the need for such a treatment. This is rarely true for well-established clinical markers such as tumor size or regional lymph node involvement. In many cases, this is also not true for biomarkers, especially when considering nontargeted therapies. Here I argue that for nontargeted treatments prognosis is often more important than interaction with treatment, because it is the absolute and not the relative benefit that matters, and when there is no treatment interaction, the same relative benefit translates into a larger absolute benefit for poor prognosis patients.


Sign in / Sign up

Export Citation Format

Share Document